Correlation between bone marrow-sparing and pathologic response in rectal cancer patients undergoing neoadjuvant chemoradiotherapy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065274

Enrollment

Unknown

Registered

2022-11-01

Start date

2022-11-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Interventions

bone marrow-sparing group:bone marrow-sparing

control group:none

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-75 years; 2. With histologically proved rectal adenocarcinoma located = 100 x 10^9/L

Exclusion criteria

Exclusion criteria: 1. Patients with acute and chronic infection, rheumatism, immune system or hematopoietic dysfunction; 2. Pregnant or lactating women; 3. With disorders of mental illness or mental retardation; 4. Patients participating in other clinical studies or drug experiments at the same time.

Design outcomes

Primary

Measure	Time frame
pathologic response;	—

Secondary

Measure	Time frame
lymphocyte counts;	—

Countries

China

Contacts

Public ContactYijun Wang

Jiangsu Province Hospital of Chinese Medicine

elevenlati@foxmail.com+86 15195959608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026